Browsing by Author "Kilic, Levent"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Axial Psoriatic Arthritis: The İmpact Of Underdiagnosed Disease On Outcomes İn Real Life
    (2018) Aydin, Sibel Zehra; Kucuksahin, Orhan; Kilic, Levent; Dogru, Atalay; Bayindir, Ozun; Ozisler, Cem; Omma, Ahmet; Tarhan, Emine Figen; Erden, Abdulsamet; Kimyon, Gezmis; Can, Meryem; Dalkilic, Ediz; Yavuz, Sule; Ureyen, Sibel Bakirci; Gunal, Esen Kasapoglu; Alhussain, Fatima Arslan; Akyol, Lutfi; Balkarli, Ayse; Yilmaz, Sema; Cinar, Muhammet; Aydin, Muge Tufan; Solmaz, Dilek; Mercan, Ridvan; Erten, Sukran; Kalyoncu, Umut; 29948352
    Psoriatic arthritis (PsA) may affect different joints, including the spine. The prevalence of spinal involvement is variable depending on the definition and a subset of patients have been identified in cohorts that do not have clinical features of axial disease and yet have imaging findings. Still, there is not a consensus on how and when to screen axial disease. In this study, we aimed to investigate factors associated with being underdiagnosed for axial psoriatic arthritis (axPsA) and its impacts on outcomes. Disease features and outcomes of axPsA according to the physician (n=415) were compared with patients with imaging findings only (sacroiliitis fulfilling the modified New York criteria, n=112), using data from a real-life PsA registry. Patients with imaging findings only were more frequently women (83/220 (37.7%) vs 29/122 (23.8%); p=0.008). This group also had higher peripheral disease activity (imaging only vs clinical AxPsA: mean (SD) tender joint count 5.3 (6.1) vs 3.3 (4.7), swollen joint count 1.9 (2.9) vs 1.2 (2.4); p<0.001 for both comparisons) and was less often treated using TNF inhibitors (16.1 vs 38.2%; p<0.001) than patients who were classified as axPsA. Patient-reported outcomes were similar in both groups. PsA patients, especially women with more severe peripheral disease, have a higher risk of being underdiagnosed for axPsA. The severity of peripheral symptoms may be a risk factor to mask the spinal features of PsA.
  • No Thumbnail Available
    Item
    Leflunomide As a Concomitant DMARD Choice for the Biological Treatment Era of Rheumatoid Arthritis
    (2018) Kimyon, Gezmis; Kiraz, Sedat; Ertenli, Ihsan; Kucuksahin, Orhan; Dalkilic, Ediz; Bes, Cemal; Kanitez, Nilufer Alpay; Kasifoglu, Timucin; Emmungil, Hakan; Coskun, Belkis Nihan; Yagiz, Burcu; Koca, Suleyman Serdar; Cinar, Muhammet; Ates, Askin; Akar, Servet; Bakirli, Duygu Ersozlu; Yazisiz, Veli; Bilge, Nazife Sule Yasar; Tufan, Muge Aydin; Karadag, Omer; Kelesoglu, Ayse Bahar; Mercan, Ridvan; Gercik, Onay; Oz, Burak; Akar, Zeynel Abidin; Yilmaz, Sedat; Turan, Sezin; Pehlivan, Yavuz; Terzioglu, Ender; Kilic, Levent; Erten, Sukran; Tekgoz, Emre; Tascilar, Koray; Kalyoncu, Umut; https://orcid.org/0000-0003-1537-2192; W-3342-2017
  • Thumbnail Image
    Item
    Methodology of a new inflammatory arthritis registry: TReasure
    (2018) Tufan, Muge Aydin; Kalyoncu, Umut; Tascilar, Etem Koray; Ertenli, Ali Ihsan; Dalkilic, Huseyin Ediz; Bes, Cemal; Kucuksahin, Orhan; Kasifoglu, Timucin; Alpay Kanitez, Nilufer; Emmungil, Hakan; Kimyon, Gezmis; Yasar Bilge, Nafize Sule; Akar, Servet; Atagunduz, Mehmet Pamir; Koca, Suleyman Serdar; Ates, Askin; Yazisiz, Veli; Terzioglu, Ender; Ersozlu, Emine Duygu; Tufan, Muge Aydin; Cinar, Muhammet; Mercan, Ridvan; Sahin, Ali; Erten, Sukran; Pehlivan, Yavuz; Yilmaz, Sedat; Kelesoglu Dincer, Ayse Bahar; Gercik, Onay; Coskun, Belkis Nihan; Yagiz, Burcu; Kaymaz Tahra, Sema; Aksoy, Aysun; Karadag, Omer; Kilic, Levent; Kiraz, Sedat; 30119164
    Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritis patients. This article reviews the methodology and objectives of the TReasure registry established to collect data from rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients. Methodology: Fifteen rheumatology centers in Turkey will contribute data to the TReasure database. The actual proprietor of the database is the Hacettepe Rheumatology Association (HRD) and Hacettepe Financial Enterprises. Pharmaceutical companies that operate in Turkey (in alphabetical or er), Abbvie, Amgen, BMS, Celltrion Healthcare, Novartis, Pfizer, Roche, and UCB, support the TReasure registry. TReasure is a web-based database to which users connect through a URL (https://www.trials-network.org/treasure) with their unique identifier and passwords provided for data entry and access. TReasure records demographic and clinical features, comorbidities, radiology and laboratory results, measures of disease activity, and treatment data. Discussion: TReasure will provide us with various types of data, such as a cross-sectional view of the current nationwide status of the patients currently receiving these treatments, and retrospective data as much as allowed by the participating centers' records. Finally, a high-quality prospective dataset will be built over the ensuing years from patients with a new diagnosis of RA or SpA.